Which has stronger earnings & valuation, CAMP or ANL?

Adlai Nortye has higher revenue and earnings than CAMP4 Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CAMP4 Therapeutics $4.22M 56.56 -$80.40M -$2.32 N/A Adlai Nortye $18.06M 55.78 -$35.53M N/A N/A

CAMP4 Therapeutics (CAMP) Competitors

$3.80 +0.08 (+2.15%)

As of 03:03 PM Eastern

Compare

CAMP vs. MLTX, KURA, ABUS, JANX, and ANL

Should you buy CAMP4 Therapeutics stock or one of its competitors? CAMP4 Therapeutics's main competitors and comparable companies include MoonLake Immunotherapeutics (MLTX), Kura Oncology (KURA), Arbutus Biopharma (ABUS), Janux Therapeutics (JANX), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CAMP4 Therapeutics compare to MoonLake Immunotherapeutics?

CAMP4 Therapeutics (NASDAQ:CAMP) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 0 mentions for CAMP4 Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat CAMP4 Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CAMP4 Therapeutics	Neutral
MoonLake Immunotherapeutics	Positive

CAMP4 Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$4.22M	56.56	-$80.40M	-$2.32	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

CAMP4 Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. MoonLake Immunotherapeutics' return on equity of -82.53% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

CAMP4 Therapeutics presently has a consensus target price of $9.79, indicating a potential upside of 157.52%. MoonLake Immunotherapeutics has a consensus target price of $24.57, indicating a potential upside of 100.17%. Given CAMP4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CAMP4 Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44

93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

MoonLake Immunotherapeutics beats CAMP4 Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Kura Oncology?

CAMP4 Therapeutics (NASDAQ:CAMP) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Kura Oncology has a net margin of -384.30% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Kura Oncology's return on equity of -207.18% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
Kura Oncology	-384.30%	-207.18%	-45.17%

CAMP4 Therapeutics currently has a consensus price target of $9.79, suggesting a potential upside of 157.52%. Kura Oncology has a consensus price target of $25.40, suggesting a potential upside of 134.04%. Given CAMP4 Therapeutics' higher probable upside, research analysts clearly believe CAMP4 Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Kura Oncology had 2 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 2 mentions for Kura Oncology and 0 mentions for CAMP4 Therapeutics. Kura Oncology's average media sentiment score of 0.46 beat CAMP4 Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
CAMP4 Therapeutics	Neutral
Kura Oncology	Neutral

CAMP4 Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

CAMP4 Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$4.22M	56.56	-$80.40M	-$2.32	N/A
Kura Oncology	$67.48M	14.31	-$278.67M	-$3.37	N/A

Summary

Kura Oncology beats CAMP4 Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Arbutus Biopharma?

CAMP4 Therapeutics (NASDAQ:CAMP) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

43.8% of Arbutus Biopharma shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arbutus Biopharma has a net margin of 84.22% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Arbutus Biopharma's return on equity of 90.98% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
Arbutus Biopharma	84.22%	90.98%	82.34%

CAMP4 Therapeutics currently has a consensus price target of $9.79, suggesting a potential upside of 157.52%. Arbutus Biopharma has a consensus price target of $5.00, suggesting a potential upside of 2.56%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe CAMP4 Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arbutus Biopharma has higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$4.22M	56.56	-$80.40M	-$2.32	N/A
Arbutus Biopharma	$14.08M	68.59	-$33.50M	$0.79	6.17

CAMP4 Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

In the previous week, Arbutus Biopharma had 1 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 1 mentions for Arbutus Biopharma and 0 mentions for CAMP4 Therapeutics. Arbutus Biopharma's average media sentiment score of 1.73 beat CAMP4 Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
CAMP4 Therapeutics	Neutral
Arbutus Biopharma	Very Positive

Summary

Arbutus Biopharma beats CAMP4 Therapeutics on 12 of the 16 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Janux Therapeutics had 3 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 3 mentions for Janux Therapeutics and 0 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 0.00 beat Janux Therapeutics' score of -0.44 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Janux Therapeutics	Neutral
CAMP4 Therapeutics	Neutral

Janux Therapeutics presently has a consensus price target of $36.46, indicating a potential upside of 118.46%. CAMP4 Therapeutics has a consensus price target of $9.79, indicating a potential upside of 157.52%. Given CAMP4 Therapeutics' higher possible upside, analysts plainly believe CAMP4 Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CAMP4 Therapeutics has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$24M	42.52	-$113.62M	-$1.64	N/A
CAMP4 Therapeutics	$4.22M	56.56	-$80.40M	-$2.32	N/A

Janux Therapeutics has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Janux Therapeutics' return on equity of -11.89% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

Janux Therapeutics has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

75.4% of Janux Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Janux Therapeutics beats CAMP4 Therapeutics on 11 of the 17 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Adlai Nortye?

CAMP4 Therapeutics (NASDAQ:CAMP) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

CAMP4 Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Adlai Nortye has higher revenue and earnings than CAMP4 Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$4.22M	56.56	-$80.40M	-$2.32	N/A
Adlai Nortye	$18.06M	55.78	-$35.53M	N/A	N/A

In the previous week, Adlai Nortye had 4 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 4 mentions for Adlai Nortye and 0 mentions for CAMP4 Therapeutics. Adlai Nortye's average media sentiment score of 0.98 beat CAMP4 Therapeutics' score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Overall Sentiment
CAMP4 Therapeutics	Neutral
Adlai Nortye	Positive

CAMP4 Therapeutics currently has a consensus target price of $9.79, indicating a potential upside of 157.52%. Adlai Nortye has a consensus target price of $29.50, indicating a potential upside of 88.62%. Given CAMP4 Therapeutics' higher probable upside, equities research analysts plainly believe CAMP4 Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Adlai Nortye has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Adlai Nortye's return on equity of 0.00% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
Adlai Nortye	N/A	N/A	N/A

35.2% of Adlai Nortye shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Adlai Nortye beats CAMP4 Therapeutics on 10 of the 13 factors compared between the two stocks.

Get CAMP4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAMP vs. The Competition

Export

Metric	CAMP4 Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$238.46M	$3.93B	$7.27B	$13.10B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.64	14.15	275.29	25.80
Price / Sales	56.56	1,484.03	682.07	97.80
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.73	15.49	10.53	6.35
Net Income	-$80.40M	-$22.82M	$3.50B	$360.12M
7 Day Performance	-5.71%	-2.02%	-0.97%	-0.07%
1 Month Performance	-12.04%	-6.47%	-3.28%	-3.35%
1 Year Performance	36.45%	31.33%	15.16%	5.57%

CAMP4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAMP CAMP4 Therapeutics	3.3727 of 5 stars	$3.80 +2.2%	$9.79 +157.5%	+46.7%	$238.46M	$4.22M	N/A	644
MLTX MoonLake Immunotherapeutics	2.3455 of 5 stars	$12.12 -0.6%	$24.57 +102.7%	-75.4%	$1.03B	N/A	N/A	130
KURA Kura Oncology	3.3772 of 5 stars	$11.38 +0.7%	$25.40 +123.1%	+34.0%	$1.01B	$67.48M	N/A	260
ABUS Arbutus Biopharma	1.6314 of 5 stars	$5.08 +0.3%	$5.00 -1.5%	+8.7%	$1.01B	$14.08M	6.42	19	Positive News
JANX Janux Therapeutics	2.5846 of 5 stars	$16.34 -0.6%	$36.46 +123.2%	-28.1%	$999.82M	$10M	N/A	113

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAMP) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CAMP4 Therapeutics (CAMP) Competitors

CAMP vs. MLTX, KURA, ABUS, JANX, and ANL

How does CAMP4 Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does CAMP4 Therapeutics compare to Kura Oncology?

Summary

How does CAMP4 Therapeutics compare to Arbutus Biopharma?

Summary

How does CAMP4 Therapeutics compare to Janux Therapeutics?

Summary

How does CAMP4 Therapeutics compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAMP vs. The Competition

CAMP4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CAMP4 Therapeutics (CAMP) Competitors

CAMP vs. MLTX, KURA, ABUS, JANX, and ANL

How does CAMP4 Therapeutics compare to MoonLake Immunotherapeutics?

Does the media refer more to CAMP or MLTX?

Which has higher earnings and valuation, CAMP or MLTX?

Which has more volatility and risk, CAMP or MLTX?

Is CAMP or MLTX more profitable?

Do analysts prefer CAMP or MLTX?

Do institutionals and insiders believe in CAMP or MLTX?

Summary

How does CAMP4 Therapeutics compare to Kura Oncology?

Is CAMP or KURA more profitable?

Do analysts prefer CAMP or KURA?

Does the media favor CAMP or KURA?

Which has more risk and volatility, CAMP or KURA?

Which has better earnings & valuation, CAMP or KURA?

Summary

How does CAMP4 Therapeutics compare to Arbutus Biopharma?

Do insiders & institutionals have more ownership in CAMP or ABUS?

Is CAMP or ABUS more profitable?

Do analysts prefer CAMP or ABUS?

Which has preferable earnings and valuation, CAMP or ABUS?

Which has more risk and volatility, CAMP or ABUS?

Does the media refer more to CAMP or ABUS?

Summary

How does CAMP4 Therapeutics compare to Janux Therapeutics?

Does the media refer more to JANX or CAMP?

Do analysts prefer JANX or CAMP?

Which has preferable earnings & valuation, JANX or CAMP?

Is JANX or CAMP more profitable?

Which has more risk and volatility, JANX or CAMP?

Do insiders & institutionals hold more shares of JANX or CAMP?

Summary

How does CAMP4 Therapeutics compare to Adlai Nortye?

Which has more risk and volatility, CAMP or ANL?

Which has stronger earnings & valuation, CAMP or ANL?

Does the media favor CAMP or ANL?

Do analysts rate CAMP or ANL?

Is CAMP or ANL more profitable?

Do insiders & institutionals believe in CAMP or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAMP vs. The Competition

CAMP4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools